A股異動 | 華大基因(300676.SZ)漲近4% 全資子公司腸癌檢測產品獲得沙特FDA批准上市
格隆匯1月7日丨華大基因(300676.SZ)現報92.15元,漲3.66%,暫成交5億元,最新市值380億元。華大基因今日午間公佈,公司全資子公司BGI Europe A/S(簡稱”歐洲醫學“)的腸癌輔助診斷產品於近日獲得Saudi Food & Drug Authority(英文簡稱”SFDA“,中文譯名”沙特阿拉伯食品藥品管理局“)批准上市。上述產品獲得SFDA批准上市,進一步擴大了公司在沙特乃至整個中東地區的影響力和業務範圍,以期助力區域腫瘤防控工作,為長期本地化發展與合作奠定基礎。此外,該次註冊獲批是公司深入拓展國際佈局,實現海外業務可持續發展的又一重要成果,有利於加速提升公司全球市場份額,進一步加強公司產品的國際競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.